peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical’s Nomination Committee appointed

27 Oct 2015, 08:30
Regulatory information
Hansa Medical AB’s Nomination Committee for the AGM 2016 will consist of Anders Blom representing Nexttobe AB, Fredrik Bogren representing Farstorps Gård AB and Astrid Samuelsson representing Handelsbanken Fonder. It also includes the chairman of the board Birgit Stattin Norinder as convener. Furthermore the company publishes the financial calendar for 2016

Anders Blom has been appointed chairman of the Nomination Committee. The Nomination Committee will propose to the AGM 2016 the chairman for the AGM, the chairman of the board, the board of directors, the directors’ fees, auditors, the auditors’ fees and principles for the Nomination Committee.

Shareholders who wish to submit proposals to the Nomination Committee can do this either by e-mail to or by mail at the following address: Hansa Medical, Nomination Committee, P.O. Box 785, SE-220 07 Lund.

The Nomination Committee’s proposals will be presented in the notice convening the AGM and on the company’s website.

The following dates have been scheduled for financial reporting during 2016:
Year-end report 2015                                    February 18, 2016
Annual report 2015                                       March 31, 2016
Interim report January – March 2016            April 27, 2016
Annual General Meeting 2016                      April 27, 2016
Interim report January – June 2016              July 21, 2016
Interim report January – September 2016    November 10, 2016

The information in this press release was released for public disclosure on October 27, 2015 at 08.30 CET.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-390 85 30

About Hansa Medical
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on First North Premier in Stockholm with Remium Nordic AB as Certified Adviser.